

## IL31 Antibody (N-term) Blocking Peptide

Synthetic peptide Catalog # BP9388a

### **Specification**

## IL31 Antibody (N-term) Blocking Peptide - Product Information

**Primary Accession** 

Q6EBC2

## IL31 Antibody (N-term) Blocking Peptide - Additional Information

**Gene ID 386653** 

### **Other Names**

Interleukin-31, IL-31, IL31

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## IL31 Antibody (N-term) Blocking Peptide - Protein Information

## Name IL31

### **Function**

Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR (PubMed:<a href="http://www.uniprot.org/citations/15184896" target="\_blank">15184896</a>). May function in skin immunity (PubMed:<a href="http://www.uniprot.org/citations/15184896" target="\_blank">15184896</a>). Enhances myeloid progenitor cell survival in vitro (By similarity). Induces RETNLA and serum amyloid A protein expression in macrophages (By similarity).

#### **Cellular Location**

Secreted.

#### **Tissue Location**

Detected at low levels in testis, bone marrow, skeletal muscle, kidney, colon, thymus, small intestine and trachea

#### IL31 Antibody (N-term) Blocking Peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

### • Blocking Peptides

## IL31 Antibody (N-term) Blocking Peptide - Images

# IL31 Antibody (N-term) Blocking Peptide - Background

IL31, which is made principally by activated Th2-type T cells, interacts with a heterodimeric receptor consisting of IL31RA (MIM 609510) and OSMR (MIM 601743) that is constitutively expressed on epithelial cells and keratinocytes. IL31 may be involved in the promotion of allergic skin disorders and in regulating other allergic diseases, such as asthma.

## IL31 Antibody (N-term) Blocking Peptide - References

Le Saux, S., et al. J. Biol. Chem. 285(5):3470-3477(2010)Zucchelli, M., et al. Inflamm. Bowel Dis. 15(7):961-962(2009)Gutzmer, R., et al. J. Allergy Clin. Immunol. 123(3):619-625(2009)Zhang, Q., et al. Cytokine Growth Factor Rev. 19 (5-6), 347-356 (2008):Werfel, T., et al. Chem Immunol Allergy 94, 101-111 (2008):